Evaluation of Personalized Nutritional Intervention Together With the Application of MSC-derived Exosomes on the Regenerative Capacity and Wound Healing of Cutaneous Ulcers in Diabetics
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Foot, Diabetic
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Ulcer evaluation
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The ageing population and the increase in diabetes raise the prevalence of chronic skin ulcers (CCU). In diabetics, precursor cell mobilization decreases. In wounds, the inflammation is prolonged and oxidative stress increases. This is an unfavorable microenvironment for healing. A major risk factor in the development of CCU is nutritional deficiency. Healing needs energy and nutrients for regeneration. In diabetics the malnutrition can be more than 60%. However, although the provision of certain nutrients can improve the healing capacity, it is not a common clinical practice to nutritionally evaluate diabetic with CCU. Exosomes are extracellular vesicles that reflect the physiological state of the cells producing them. Stem cell derivatives exosomes are rich in factors, that can provide a favorable microenvironment for tissue regeneration.
The aim of this project is to develop a therapeutic process to accelerate the healing of diabetic CCU, based on the correction of nutritional deficiencies, to improve the regenerative capacity, together with the application of exosomes from mesenchymal stem-cell (MSC) in the wound, creating a microenvironment that favors tissue regeneration. For this, a pilot clinical trial with diabetic patients with CCU is proposed, to evaluate the effect of personalized nutritional supplementation on healing and regenerative capacity.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signature of the informed consent
- •Age between 50 and 80 years
- •Diagnosis of Diabetes Mellitus for more than 1 year
- •Documented diagnosis of peripheral artery disease
- •HbA1c \< 9%
- •Category 5 in the Rutherford-Becker classification
Exclusion Criteria
- •Poor cognitive function, dementia or psychiatric conditions
- •Osteomyelitis, gangrene, malignancy or immunocompromised disease
- •Thromboangiitis obliterans or Buerger's disease
- •Clinical evidence of invasive infection in the target limb requiring IV antibiotherapy
- •Presence of neuropathic ulcers only
- •Human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV) positive.
Outcomes
Primary Outcomes
Ulcer evaluation
Time Frame: Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation
Change from baseline in size ulcer assessed by picture, including ruler to measure their size
Secondary Outcomes
- Composite measure of markers of nutritional status(Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation)
- Composite measure of haemogram(Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation)
- Concentration of stromal cell-derived factor 1 (SDF-1) and vascular endothelial growth factor A (VEGFA)(Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation)
- Hemoglobin A1c (HbA1c) Test for Diabetes(Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation)
- Measure of markers of nutritional status, include to thyrotropin(Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation)
- Ultrasensitive C-reactive Protein (CRP) test(Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation)
- Quantification of circulating endothelial progenitor cells (EPC)(Baseline, 30 days after treatment initiation, 60 days after treatment initiation and 90 days after treatment initiation)